Text sizing:
A
A
A
Oncology Times:
doi: 10.1097/01.COT.0000440869.25906.c6
Correction

Correction

Free Access

In the article, “Will the Costs of Cancer Care Ever Come Down? Speakers at AACI Meeting Discuss the Nuances of the Question,” in the November 10 issue (http://bit.ly/OT-Costs-Nov102013), information noted at the meeting about the cost for ipilimumab (Yervoy) was incorrect. As we have since been informed by a spokesperson for the drug's manufacturer, Bristol-Myers Squibb, “per the U.S. labeling, a complete course of treatment with Yervoy 3 mg/kg includes four infusions over three months and costs approximately $30,000 per infusion (this translates to a cost of approximately $120,000 for a course of therapy). The administration of Yervoy is different than most other medicines for advanced disease, which are commonly administered until progression.” We regret the error.

© 2013 by Lippincott Williams & Wilkins, Inc.

More on ONCOLOGY-TIMES.com...
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!

                         

Login

Article Tools

Share